Clinical Observation And Experimental Study Of Xiaoyaosan Treating Liver Stagnation And Spleen Deficiency Syndrome Of Alzheimer’s Disease

Objective Clinical observation : To observe the clinical curative effect of Xiaoyaosan treating liver stagnation and spleen deficiency syndrome of Alzheimer’s disease, and to evaluate its effectiveness. Animal experiment:To establish the mouse model of liver stagnation and spleen deficiency syndrome of Alzheimer’s disease. Then to observe the influence on the behavior of mice and free radical metabolism indexes of SOD and MDA and neurotransmitter 5-HT and NA after the treating of Xiaoyaosan.Then to explore its possible mechanism of action.Methods Clinical observation:Adopting random control design, to select 40 cases of liver and spleen deficiency in patients with AD of the neurology clinic of Wuhan No.1 Hospital. Randomly divide into treatment group 20 cases and control group 20 cases. The same basic treatment was given at the same time in the treatment group and the control group,the treatment group was also treated with Xiaoyaosan, and the treatment course was 12 weeks. Before and after the treatment, to evaluate the scores of MMSE and ADL and the TCM Syndromes and the safety,and to assess the clinical total efficacy of TCM. Animal experiment:50 BALB/c mice were randomly divided into five groups, they were blank control group, D-galactose group,compound model group, Xiaoyaosan group, Escitalopram group. The blank control group was given 0.9% physiological saline with subcutaneous injection of the back of the neck, while D-galactose group, compound model group, Xiaoyaosan group and Escitalopram group were given 120mg/kg D-galactose solution for 42 days. On the twenty-ninth day, Xiaoyaosan group was given Xiaoyaosan 13g/kg.d,while Escitalopram group was given Escitalopram 10mg/kg.d for 14 days; after the completion of gavage, compound model group, Xiaoyaosan group and Escitalopram group were given chronic restraint stress stimulation for 6 hours everyday,last for 14 days. After the experiment, to conduct the dark avoidance test and field test on the mice, then to test the content of free radical metabolism index of SOD and MDA and the content of 5-HT and NA of serum.Results Clinical observation:(1)Comparing the score of MMSE and ADL of two groups before and after the treatment(P<0.05),indicating that the treatment group and control group can improve cognitive function and the ability of daily life in elderly patients with dementia; Comparing the score of MMSE and ADL of two groups after the treatment(P<0.05), indicating that the effect of the treatment group is better than the control group(P<0.05).(2)The total effective rate of the treatment group was 75%, while the total effective rate of the control group of was 50%.It is indicating that the curative effect of the treatment group is better than the control group(P<0.05).(3)There were no toxic side effects and adverse events on the patients of treatment group and control groupbefore and after treatment,so the treatment is safe and reliable. Animal experiment:Dark avoidance test results show that, compared with the control group and D-galactose group, the latency of compound model group was shortened and the error number was increased(P<0.05);compared with the compound model group, the latency of Xiaoyaosan group and Escitalopram group were extended and the number of errors were reduced(P<0.05); There were no obvious difference on Xiao Yaosan group and Escitalopram group(P>0.05).Field test results show that, compared with the control group and D-galactose group, the central region distance and the total distance of the compound model were decreased, and the activity was also decreased(P<0.05);compared with the compound model group, the central region distance and the total distance of Xiaoyaosan group and Escitalopram group were increased, and the activity were also raised(P<0.05); There were no obvious difference on Xiao Yaosan group and Escitalopram group(P>0.05).The free radical metabolism index SOD and MDA results show that, compared with the control group and D-galactose group, the content of SOD of the compound model group was decreased, while the content of MDA was increased(P<0.05);compared with the compound model group, the content of SOD of Xiao Yaosan group and Escitalopram group were increased, while the content of MDA were decreased(P<0.05). There were no obvious difference on Xiao Yaosan group and Escitalopram group(P>0.05).The 5-HT and NA of serum results show that, compared with the control group and D-galactose group, the content of 5-HT and NA of serum.of compound model group were significantly decreased(P<0.05);compared with the compound model group, the contentof 5-HT and NA of serum of Xiaoyaosan group and Escitalopram group were elevated(P<0.05),and Xiao Yaosan group increased more obviously than Escitalopram group(P<0.05).Conclusion Clinical observation:Xiaoyaosan is effective and safe on the treatment of liver stagnation and spleen deficiency syndrome of Alzheimer’s disease. It can obviously improve the learning and memory ability of patients, and reduce the clinical symptoms, and improve the patient’s ability of life. So it is worthy of our further study and clinical application. Animal experiment : Xiaoyaosan can obviously improve the Abnormal behavior of mice with liver stagnation and spleen deficiency syndrome of Alzheimer’s disease, and reduce free radical damage, and increase the content of 5-HT and NA of serum. At the same time, Xiaoyaosan ’ s effect is better than escitalopram at the treatment of this model mice.